• Publications
  • Influence
Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor
Thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke often result in long‐term disability and/or mortality. The anticoagulants currentlyExpand
  • 52
  • 3
Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
BACKGROUND Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. It is indicated for healing all gradesExpand
  • 19
  • 1
  • PDF
Economic Impact of Implementing Pneumonia Treatment Guidelines for Intravenous to Oral Conversion
Background Inpatient treatment of pneumonia produces significant costs to the health care system. In an effort to improve quality of care, decrease length of stay, and decrease drug costs associatedExpand
  • 1
Clostridium difficile—Associated Diarrhea, an Emerging Epidemic: Therapeutic Options
Clostridum difficile—associated disease (CDAD) is the leading cause of infectious diarrhea and is associated with considerable morbidity and mortality. The incidence is estimated to range from 3.4 toExpand
  • 1
The Administration of rt-PA (Activase®) for the Treatment of Empyema in an Adult Patient
The administration of various fibrinolytic agents for the treatment of empyema has been reported in past studies. Most of the current literature has shown favorable outcomes in terms of increasedExpand
  • 1
Ramoplanin: A Promising Treatment Option for Clostridium difficile -Associated Diarrhea and Vancomycin-Resistant Enterococcus
INTRODUCTION The emergence of resistant path ogens, along with a lack of novel anti microbial agents in the pharmaceutical pipeline, is becoming a growing problem in treating nosocomial infections.Expand
  • 1
  • PDF